Hanmi Science

At a glance

Hanmi Science filed 170 disclosures in the last 12 months, including 43 insider, 37 5% holder, 9 buyback, 4 earnings and 2 contract. The most recent key filing was on Oct 30.

Revenue for 2025 was ₩1.36T, up 5.7% on 2024. Operating margin was 10.2% against 7.7% a year earlier. Debt was 55% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩722B and operating profit of ₩92.7B.

The 2025 annual report lists 489 employees with an average tenure of 7 years and average pay of ₩72.7M, #525 of 1,829 listed companies by average pay. Its 10 directors and auditors were paid ₩388M each on average. It paid ₩300 per common share in cash dividends, against ₩300 a year earlier (+0%). 송영숙 and related parties held 55.84% at year end.

Of 2 recent 5%+ holder reports, 0 raised and 0 cut a stake; the largest stake reported was 71.15% on Oct 30.

From the 2025 annual report

Staff: 489 (312 men, 177 women), of whom 12 on fixed-term contracts. Total pay for the year: ₩35.5B. Directors and auditors: 10, paid ₩3.9B in total.

Dividends (common shares)

Largest shareholder

송영숙 holds 3.38%; with 25 related parties the group holds 55.84% of common shares at year end (from 64.23% at the start of the year).

Individuals paid ₩500M or more

Auditor: 안진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports